Why the study?
To review the current indications and evidence for levosimendan and milrinone across various clinical scenarios, including acute heart failure, advanced cardiac failure, cardiac surgery, and sepsis.
Does levosimendan improve hemodynamic outcomes and mortality compared to milrinone in patients with heart failure, cardiac surgery, or sepsis?
Comparison
Levosimendan vs milrinone
Design
Narrative review
Key result
Levosimendan appears superior to milrinone for hemodynamic favorability in cardiac surgery and is linked to lower mortality than placebo in septic shock.
Authors
Loading...
May favor levosimendan in postoperative hemodynamics; hypothesis-generating for septic shock mortality pending RCTs.
Does levosimendan improve hemodynamic outcomes and mortality compared to milrinone in patients with heart failure, cardiac surgery, or sepsis?
This narrative review suggests levosimendan may offer superior hemodynamic benefits over milrinone in cardiac surgery and lower mortality than placebo in septic shock, though further research is needed.
Quintero-Altare et al. (2024) conducted a review in Acute heart failure, advanced cardiac failure, cardiac surgery, and sepsis. Levosimendan vs. Milrinone, dobutamine, or placebo was evaluated. Levosimendan appears superior to milrinone for hemodynamic favorability in cardiac surgery and is linked to lower mortality than placebo in septic shock.